News | February 25, 2009

Some Cath Lab Directors Say CVIS Deliver Limited Financial Benefits, Satisfaction

February 23, 2009 - Cardiovascular information systems (CVIS) are not delivering quantifiable financial benefits, according to cardiac cath lab directors who participated in an independent national survey completed in January on behalf of Wolters Kluwer Health and ProVation Medical.

The survey of hospital cardiac cath lab directors was designed to measure the use and satisfaction levels with CVIS and procedure documentation systems.

Thirty one percent of cardiac cath lab directors reported no quantifiable improvements in revenues or the revenue cycle since implementing CVIS, due in part to continued reliance on dictation for physician documentation. Overall, 69 percent of respondents reported that physicians continue to dictate, despite clinical procedure documentation for physicians being identified by 51 percent of cardiology directors as an “extremely important” CVIS feature.

Four in 10 cardiac cath lab directors whose physicians dictate felt that documentation issues have at least a “moderate” impact on revenues. One-fourth also estimated that they could realize an annual savings of $100,000 or more by eliminating the costs associated with dictation and transcription.

“When properly designed and implemented, technological systems for cardiology should streamline workflow, reduce costs and increase revenue,” said Arvind Subramanian, president and CEO of Wolters Kluwer Health Clinical Solutions and ProVation Medical. “However, when they are difficult to use, don’t offer a solid return on investment (ROI) or do not integrate with other information systems, they cannot deliver the full scope of improvements health care organizations require to achieve their patient care and financial goals.”

This was borne out in the survey. The majority of respondents reported being only “somewhat satisfied” or “satisfied” with CVIS. Lower satisfaction rates were most closely associated with problems interfacing with other systems and hardware (10 percent); failure to function as promised (8 percent); not user-friendly (7 percent); poor vendor support (6 percent); and failure to offer a comprehensive array of features (5 percent).

Of the 31 percent who reported using software for procedure documentation, fewer than one in five said the application produced automatic CPT and ICD codes based on that documentation. As a result, 22 percent reported no quantifiable increase in revenues since implementing the documentation solution.

However, interest in clinical documentation software remains high. The majority (68 percent) of those whose physicians currently dictate said it was at least “somewhat likely” that they would implement physician procedure documentation within the next two years. Among the features identified as having the most influence over that purchasing decision were the ability to streamline workflows and increase efficiencies (88 percent), ease-of-use (86 percent) and physician satisfaction rates (72 percent).

By eliminating transcription and automating the documentation and coding processes, software can help deliver a solid ROI through reduced costs and improved reimbursement levels, the company said.

Renaissance Research, of Edwardsville, IL, conducted the national online survey Jan. 13-25, 2009. The survey was completed by 151 hospital cardiology and cardiac lab directors, providing a margin of error of +/- 8 percentage points.

ProVation MD software helps in procedure documentation, coding compliance and replaces dictation/transcription. The company will be exhibiting its ProVation MD Cardiology software at the American College of Cardiology’s 58th Annual Scientific Session in March 29–31, in Orlando.

For more information: www.provationmedical.com


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now